Talk to the Institute
Published mark

Aquestive Therapeutics, Inc.

NASDAQ: AQST. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5
SEC CIK
0001398733
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
Newest evidence
May 3, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Not published
Chair
Not published
Independent
6 / 77 directors published
Published claims
284 distinct sources
Evidence records
120 pinned
Source conflicts
0None open

Built from 4 distinct sources and 12 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

EXECUTIVE APPOINTED

Daniel Barber executive of Aquestive Therapeutics, Inc., effective 2026-04-24.

EffectiveEffective Apr 24, 2026E7

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Named Executive Officer / DirectorDaniel BarberApr 2026currentSource reportedE7
Named Executive OfficerLori J. BraenderApr 2026currentSource reportedE8
Chief Financial OfficerA. Ernest Toth, Jr.Not capturedunknownSource reportedE3
Chief Innovation and Technology OfficerA. Mark SchobelNot capturedunknownSource reportedE4
Chief Medical OfficerCarl N. KrausNot capturedunknownSource reportedE5
Chief Operating OfficerCassie JungNot capturedunknownSource reportedE6
Senior Vice President Regulatory AffairsMelina T. CioffiNot capturedunknownSource reportedE9
Senior Vice President Information Technology, Human Resources and CommunicationsPeter BoydNot capturedunknownSource reportedE10
Senior Vice President Sales and MarketingSherry KorczynskiNot capturedunknownSource reportedE11

Board of directors

Evidence

7 directors published. 6 of 7 with a published determination are independent.

DirectorStatusSinceCommitteesClaim
Abigail L. JenkinsIndependent2024None publishedSource reportedE2
Daniel BarberNot independent2022None publishedSource reportedE2
Gregory B. Brown, M.D.Independent2007None publishedSource reportedE2
John S. CochranIndependent2004None publishedSource reportedE2
Julie Krop, M.D.Independent2021None publishedSource reportedE2
Marco Taglietti, M.D.Independent2021None publishedSource reportedE2
Timothy E. MorrisIndependent2022None publishedSource reportedE2
Abigail L. JenkinsIndependence not publishedNot publishedNominating and GovernanceSource reportedE12
John S. CochranIndependence not publishedNot publishedCompensation, chairNominating and GovernanceSource reportedE12
Timothy E. MorrisIndependence not publishedNot publishedAudit, chairCompensationSource reportedE12

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
AuditTimothy E. MorrisTimothy E. MorrisNot described in the published record
CompensationJohn S. CochranJohn S. Cochran, Timothy E. MorrisNot described in the published record
Nominating and GovernanceNot publishedAbigail L. Jenkins, John S. CochranNot described in the published record
Committee AppointmentTimothy E. Morris: chair, Audit
Source reportedE12
company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5:committee_appointment:22
Committee AppointmentJohn S. Cochran: chair, Compensation
Source reportedE12
company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5:committee_appointment:24
Committee AppointmentTimothy E. Morris: member, Compensation
Source reportedE12
company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5:committee_appointment:25
Committee AppointmentAbigail L. Jenkins: member, Nominating and Governance
Source reportedE12
company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5:committee_appointment:27
Committee AppointmentJohn S. Cochran: member, Nominating and Governance
Source reportedE12
company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5:committee_appointment:28

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingAQST (NASDAQ)
Source reportedE1
company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5:security_listing:29
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 17, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameAquestive Therapeutics, Inc.
Source reportedE1
company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
12 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    Aquestive Therapeutics, Inc. DEF 14A 2025-04-25
    sec proxy. Published Apr 25, 2025. Retrieved Apr 24, 2026. Cited by 7 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    AQST executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    AQST executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    AQST executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    AQST executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    AQST DEF 14A executive officers
    sec filing. Published Apr 24, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  8. E8
    AQST DEF 14A executive officers
    sec filing. Published Apr 24, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  9. E9
    AQST executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  10. E10
    AQST executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  11. E11
    AQST executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  12. E12
    Audit
    board_seats. board seats. Cited by 8 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 16, 2026
  • Daniel Barber executive of Aquestive Therapeutics, Inc., effective 2026-04-24.
  • Lori J. Braender executive of Aquestive Therapeutics, Inc., effective 2026-04-24.
  • Abigail L. Jenkins seat on Aquestive Therapeutics, Inc., effective 2024-01-01.
  • Daniel Barber seat on Aquestive Therapeutics, Inc., effective 2022-01-01.
  • Timothy E. Morris seat on Aquestive Therapeutics, Inc., effective 2022-01-01.
  • Julie Krop, M.D. seat on Aquestive Therapeutics, Inc., effective 2021-01-01.
  • Marco Taglietti, M.D. seat on Aquestive Therapeutics, Inc., effective 2021-01-01.
  • Gregory B. Brown, M.D. seat on Aquestive Therapeutics, Inc., effective 2007-01-01.
  • John S. Cochran seat on Aquestive Therapeutics, Inc., effective 2004-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/aquestive-therapeutics-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership9
  4. Board10
  5. Committees3
  6. Control and voting0
  7. Authority to act3
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people19
  17. Subject and corrections6
  18. Evidence12
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:a2ff5150-4186-458e-a795-2eb0e1a2cfc5
  • Cite this recordAquestive Therapeutics, Inc.
  • Copy canonical URLregistry.alpha.ac/companies/aquestive-therapeutics-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    Aquestive Therapeutics, Inc.Company
  • Daniel BarberPerson
  • Lori J. BraenderPerson
  • A. Ernest Toth, Jr.Person
  • A. Mark SchobelPerson
  • Carl N. KrausPerson
  • Cassie JungPerson
  • Melina T. CioffiPerson
  • Peter BoydPerson
  • Sherry KorczynskiPerson
  • Abigail L. JenkinsPerson
  • Daniel BarberPerson
  • Gregory B. Brown, M.D.Person
  • John S. CochranPerson
  • Julie Krop, M.D.Person
  • Marco Taglietti, M.D.Person
  • Timothy E. MorrisPerson
  • Abigail L. JenkinsPerson
  • John S. CochranPerson
  • Timothy E. MorrisPerson
  • Sections
    OverviewAquestive Therapeutics, Inc.
  • MonitoringAquestive Therapeutics, Inc.
  • LeadershipAquestive Therapeutics, Inc.
  • BoardAquestive Therapeutics, Inc.
  • CommitteesAquestive Therapeutics, Inc.
  • Control and votingAquestive Therapeutics, Inc.
  • Authority to actAquestive Therapeutics, Inc.
  • FinancialsAquestive Therapeutics, Inc.
  • GovernanceAquestive Therapeutics, Inc.
  • RiskAquestive Therapeutics, Inc.
  • AI oversightAquestive Therapeutics, Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.